hist161246Referred to the committee on Health, January 13, 2023. Relating to scheduling Alfaxalone.
Submitted by the Controlled Substances Board.
hist161062Report received from Agency, January 3, 2023. hist161247Referred to the committee on Health, January 13, 2023. Relating to Excluding 6-beta-Naltrexol.
Submitted by the Controlled Substances Board.
hist161061Report received from Agency, January 3, 2023. hist161248Referred to the committee on Health, January 13, 2023. Relating to scheduling Fospropofol.
Submitted by the Controlled Substances Board.
hist161060Report received from Agency, January 3, 2023. hist161249Referred to the committee on Health, January 13, 2023. Relating to scheduling Embutramide.
Submitted by the Controlled Substances Board.
hist161059Report received from Agency, January 3, 2023. hist161250Referred to the committee on Health, January 13, 2023. Relating to scheduling Perampanel.
Submitted by the Controlled Substances Board.
hist161058Report received from Agency, January 3, 2023. hist161251Referred to the committee on Health, January 13, 2023. Relating to scheduling Lacosamide.
Submitted by the Controlled Substances Board.